A hugely disappointing first quarter for Amgen (Nasdaq: AMGN) saw revenues slide to $5.9 billion, down from $6.2 billion and below most analysts’ expectations.
Shares in the company fell 2% on Tuesday, and continued falling a further 3% in after-hours trading.
Chief executive Robert Bradway explained that the firm’s performance was hit by the coronavirus pandemic, with more people staying at home instead of visiting their doctor. March is also traditionally a slow month, the firm said.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze